These results provide support for the hypothesis that B1R might be a novel, valid pharmacological target for detecting malignant astrocytoma, manipulating newly forming vasculature integrity, and regulating tumor permeability using potent B1R agonists in preclinical and clinical settings. The gene discussed is BDKRB1; the disease is astrocytoma (excluding glioblastoma).